Xbrane Biopharma and STADA have announced that they have entered into a collaboration agreement for the development of a ranibizumab biosimilar, referencing Lucentis, which will prospectively be sold as Xlucane, in the US, European, and other markets.
Xbrane Biopharma and STADA have announced that they have entered into a collaboration agreement for the development of a ranibizumab biosimilar, referencing Lucentis, which will prospectively be sold as Xlucane, in the US, European, and other markets.
The agreement stipulates that each organization must equally contribute to development expenses and share profits from commercialization of the potential biosimilar in an equal split. Additionally, STADA will make an upfront payment to Xbrane of approximately $8.7 million (€7.5 million).
“The co-development deal with STADA is a significant achievement and opportunity for Xbrane which confirms Xbrane’s unique capabilities and competencies in biosimilar development,” said Anders Tullgren, chairman of the board of directors at Xbrane, in a prepared statement.
Xbrane will be responsible for developing the biosimilar until submissions for regulatory approval are made to the European Medicine’s Agency (EMA) and the FDA. STADA will hold the marketing authorizations and will also be accountable for the sales and marketing of the product across all territories included in the agreement (Europe, the United States, the Middle East and North Africa, and Asia).
The organizations have indicated that they are ready to move forward with the initiation of a phase 1 and phase 3 clinical trial, and say that they have agreed on the study design with both the EMA and FDA. The study will enroll patients with wet age-related macular degeneration across 16 countries.
“The deal will contribute significant funding and expertise for the development and commercialization of Xulcane and will help to accelerate the development of our pipeline of biosimilars, as well as the transformation of Xbrane into a major player in the fast-growing global biosimilars market,” said Tullgren.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.